Posted by Two Blokes
VettaFi's Head of Research Todd Rosenbluth discussed the Franklin International Low Volatility High Dividend I
Source: Two Blokes Trading
Posted by Two Blokes
LH tops Q2 estimates with double-digit EPS growth, margin gains and a raised 2025 outlook, lifting shares pre-
Source: Two Blokes Trading
Posted by Two Blokes
BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent loss
Source: Two Blokes Trading
Posted by Two Blokes
DOW posts a wider-than-expected Q2 loss and misses sales targets as pricing pressure and volume declines weigh
Source: Two Blokes Trading
Posted by Two Blokes
LULU bets big on technical gear and global reach to spark 2H25 growth amid cost pressures and cautious U.S. de
Source: Two Blokes Trading
Posted by Two Blokes
RHHBY posts solid first-half 2025 growth on strong drug demand, but pipeline setbacks and biosimilar hits rema
Source: Two Blokes Trading
Posted by Two Blokes
West Pharmaceutical's second-quarter top line continues to benefit from revenue growth in its Proprietary Prod
Source: Two Blokes Trading
Posted by Two Blokes
NextEra Energy has reliably grown its payout to shareholders for 30 years. NEE also appears to be positioned f
Source: Two Blokes Trading
Posted by Two Blokes
USANA Health Sciences is resurfacing as an idea after a strong Q2 report. The direct selling business has cont
Source: Two Blokes Trading
Posted by Two Blokes
ACGL's Q2 results are likely to reflect rate increases, new business opportunities, growth in invested asset b
Source: Two Blokes Trading
Posted by Two Blokes
SYY's Q4 gains likely stem from U.S. Foodservice strength, global growth moves and sharper cost efficiencies.
Source: Two Blokes Trading
Posted by Two Blokes
While Intel's (INTC) earnings for the quarter aren't expected to bring fireworks, Marley Kayden says investors
Source: Two Blokes Trading